Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

This clinical-stage biotech focused on precision medicines for kidney and metabolic diseases just reported a notable insider ...

Maze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney Disease

Maze Therapeutics (NASDAQ:MAZE) outlined positive Phase II results from its open-label HORIZON study evaluating MZE829 in ...
Fierce Biotech

After ph. 2 readout, analysts herald 'best-in-class potential' for Maze kidney candidate as stock plummets

Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its ...

Here is why Maze Therapeutics (MAZE) is Among the Top 8 Oversold Strong Buy-Rated Stocks

On March 31, 2026, JPMorgan raised the price target on Maze Therapeutics, Inc. (NASDAQ:MAZE) to $58 from $52 and maintained ...
BioSpace

Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data

Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung ...
FiercePharma

Maze Therapeutics referred to federal marketing regulators over challenge brought by Vertex

After Maze Therapeutics opted not to participate in the National Advertising Division’s (NAD’s) self-regulatory process for monitoring promotional claims, a case brought by competitor Vertex ...
MedCity News

Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for $800M

An experimental Maze Therapeutics drug increased urinary excretion of compounds that are biological indicators of metabolic disease, early clinical trial results that suggest the molecule has ...

Maze Therapeutics falls despite positive mid-stage trial data for lead asset

Maze Therapeutics (MAZE) plunged ~37% on Wednesday despite reporting encouraging initial data from a Phase 2 trial for its lead asset, MZE829, targeted at broad APOL1-mediated kidney disease, a ...